Publications

BibTex format

@article{Moshe:2021,
author = {Moshe, M and Daunt, A and Flower, B and Simmons, B and Brown, JC and Frise, R and Penn, R and Kugathasan, R and Petersen, C and Stockmann, H and Ashby, D and Riley, S and Atchison, C and Taylor, GP and Satkunarajah, S and Naar, L and Klaber, R and Badhan, A and Rosadas, C and Marchesin, F and Fernandez, N and Sureda-Vives, M and Cheeseman, H and O'Hara, J and Shattock, R and Fontana, G and Pallett, SJC and Rayment, M and Jones, R and Moore, LSP and Ashrafian, H and Cherapanov, P and Tedder, R and McClure, M and Ward, H and Darzi, A and Cooke, GS and Barclay, WS and On, behalf of the REACT Study team},
journal = {BMJ: British Medical Journal},
pages = {1--8},
title = {SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (REACT2): diagnostic accuracy study},
url = {https://www.bmj.com/content/372/bmj.n423},
volume = {372},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Objective: To evaluate the performance of new lateral flow immunoassays (LFIAs) suitable for use in a national COVID-19 seroprevalence programme (REACT2).Design: Laboratory sensitivity and specificity analyses were performed for seven LFIAs on a minimum of 200 sera from individuals with confirmed SARS-CoV-2 infection, and 500 pre-pandemic sera respectively. Three LFIAs were found to have a laboratory sensitivity superior to the finger-prick sensitivity of the LFIA currently used in REACT2 seroprevalence studies (84%). These LFIAs were then further evaluated through finger-prick testing on participants with confirmed previous SARS-CoV-2 infection. Two LFIAs (Surescreen, Panbio) were evaluated in clinics in June-July, 2020, and a third LFIA (AbC-19) in September, 2020. A Spike protein enzyme-linked immunoassay (S-ELISA) and hybrid double antigen binding assay (DABA) were used as laboratory reference standards.Setting: Laboratory analyses were performed at Imperial College, London and University facilities in London, UK. Research clinics for finger-prick sampling were run in two affiliated NHS trusts.Participants: Sensitivity analysis on sera were performed on 320 stored samples from previous participants in the REACT2 programme with confirmed previous SARS-CoV-2 infection. Specificity analysis was performed using 1000 pre-pandemic sera. 100 new participants with confirmed previous SARS-CoV-2 infection attended study clinics for finger-prick testing.Main outcome measures: The accuracy of LFIAs in detecting IgG antibodies to SARS-CoV-2 in comparison to two in-house ELISAs.Results: The sensitivity of seven new LFIAs using sera varied between 69% and 100% (vs S-ELISA/hybrid DABA). Specificity using sera varied between 99.6% and 100%.  Sensitivity on finger-prick testing for Panbio, Surescreen and AbC-19 was 77% (CI 61.4 to 88.2), 86% (CI 72.7 to 94.8) and 69% (CI 53.8 to 81.3) respectively vs S-ELISA/hybrid DABA. Sensitivity for sera from matched clinical samples performe
AU  - Moshe,M
AU  - Daunt,A
AU  - Flower,B
AU  - Simmons,B
AU  - Brown,JC
AU  - Frise,R
AU  - Penn,R
AU  - Kugathasan,R
AU  - Petersen,C
AU  - Stockmann,H
AU  - Ashby,D
AU  - Riley,S
AU  - Atchison,C
AU  - Taylor,GP
AU  - Satkunarajah,S
AU  - Naar,L
AU  - Klaber,R
AU  - Badhan,A
AU  - Rosadas,C
AU  - Marchesin,F
AU  - Fernandez,N
AU  - Sureda-Vives,M
AU  - Cheeseman,H
AU  - O'Hara,J
AU  - Shattock,R
AU  - Fontana,G
AU  - Pallett,SJC
AU  - Rayment,M
AU  - Jones,R
AU  - Moore,LSP
AU  - Ashrafian,H
AU  - Cherapanov,P
AU  - Tedder,R
AU  - McClure,M
AU  - Ward,H
AU  - Darzi,A
AU  - Cooke,GS
AU  - Barclay,WS
AU  - On,behalf of the REACT Study team
EP  - 8
PY  - 2021///
SN  - 0959-535X
SP  - 1
TI  - SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (REACT2): diagnostic accuracy study
T2  - BMJ: British Medical Journal
UR  - https://www.bmj.com/content/372/bmj.n423
UR  - http://hdl.handle.net/10044/1/86108
VL  - 372
ER  -

Download

ProfessorHelenWard

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)